NCT05873426View on ClinicalTrials.gov

Mass Balance Study of [14C]ZSP1273 in Healthy Adult Male Subjects in China

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 25, 2023

Primary Completion Date

April 28, 2023

Study Completion Date

April 28, 2023

Conditions
Pharmacokinetics
Interventions
DRUG

[14C] ZSP1273

600 mg suspension containing 50μCi of \[14C\]ZSP1273

Trial Locations (1)

Unknown

The First affiliated hospital of Suzhou university, Suzhou

All Listed Sponsors
lead

Guangdong Raynovent Biotech Co., Ltd

INDUSTRY